Peptides for Weight Loss: Evidence-Based Guide (2026)

What the data actually shows on GLP-1, GIP, glucagon, and amylin peptides for weight loss — mechanisms, real-world results, side effects, and how the major options compare.

Published Jun 14, 20267 min read

The most-studied peptides for weight loss target the body's appetite, satiety, and glucose-regulation pathways — primarily the GLP-1, GIP, glucagon, and amylin receptors. The FDA-approved options (Semaglutide, Tirzepatide) produce 14–22% mean body-weight reduction at 68–72 weeks in trials. Newer trial-stage compounds (Retatrutide, Cagrilintide, Survodutide, Mazdutide, Orforglipron) target the same biology with different receptor combinations and either similar or larger weight-loss numbers. This guide summarizes what the evidence shows, how the options compare, and how to think about them.

This article is informational and not medical advice. Weight-loss peptide therapy is a clinician-supervised activity; see are peptides safe? for the safety frame and the about page for editorial policy.

The biology in one paragraph

Three families of gut hormones do most of the work that peptide weight-loss drugs imitate:

GLP-1 (glucagon-like peptide-1) — released by L-cells in the intestine after eating. Slows gastric emptying, increases satiety, and (in the pancreas) increases glucose-dependent insulin release. Native GLP-1 has a half-life of about two minutes; the drugs are modified analogs that survive much longer.
GIP (glucose-dependent insulinotropic peptide) — released by K-cells in the duodenum. Augments insulin response and modulates fat metabolism.
Glucagon — counterintuitive but useful in agonism: increases energy expenditure and lipolysis when the appetite-suppressing partner receptors are also engaged.
Amylin — co-secreted with insulin from pancreatic β-cells. Slows gastric emptying and amplifies satiety. The amylin analog Cagrilintide is the leading example.

Modern weight-loss peptides hit one, two, or all three of these in combination.

The major options

Peptide	Class	Approval status	Trial weight loss
Semaglutide (Ozempic, Wegovy)	GLP-1 mono	FDA-approved	~15% at 68 weeks (STEP 1)
Tirzepatide (Mounjaro, Zepbound)	GIP + GLP-1 dual	FDA-approved	~21% at 72 weeks (SURMOUNT-1)
Liraglutide (Saxenda)	GLP-1 mono	FDA-approved	~8% at 56 weeks
Cagrilintide	Amylin mono	Phase 3 (CagriSema trial)	~10% mono; ~17% with Semaglutide
Retatrutide	GLP-1 + GIP + glucagon triple	Phase 3	~24% at 48 weeks (Phase 2 data)
Survodutide	GLP-1 + glucagon dual	Phase 3	~19% at 46 weeks (Phase 2)
Mazdutide	GLP-1 + glucagon dual	Phase 3 (China)	~15% at 48 weeks
Orforglipron	Oral small-molecule GLP-1	Phase 3 (ATTAIN)	~14% at 36 weeks
AOD-9604	hGH fragment 176-191	Research-use	Small effect, weak human data
HGH Fragment 176-191	hGH fragment	Research-use	Same as above

Per-drug research summaries: Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Survodutide, Mazdutide, Orforglipron, AOD-9604.

What the evidence shows by mechanism

GLP-1 monoagonists (Semaglutide, Liraglutide)

The most-studied option. The STEP trial program for Semaglutide established ~15% mean weight loss at 68 weeks across multiple cohorts including patients with type 2 diabetes (slightly less weight loss in T2D), non-diabetic obesity, and adolescents. Cardiovascular-outcome data (SELECT trial) showed a 20% relative reduction in major adverse cardiovascular events. Liraglutide is older, daily-dosed, and has a weaker weight-loss effect (~8%) but a longer track record.

Real-world data is broadly consistent with trials, with two caveats: real-world adherence is lower (people quit due to side effects or cost), and real-world dose escalation is often slower or stops at lower doses, producing smaller weight-loss numbers than trial maximums.

GIP + GLP-1 dual agonists (Tirzepatide)

The SURMOUNT trial program established ~21% mean weight loss at 72 weeks at the 15 mg weekly dose — a meaningfully larger effect than Semaglutide head-to-head. The mechanism is debated: GIP agonism by itself doesn't reliably cause weight loss in trials, but the combination with GLP-1 appears synergistic. Side-effect profile is broadly similar to Semaglutide (GI-dominated) but somewhat better tolerated at matched-efficacy doses.

GLP-1 + GIP + glucagon triple agonism (Retatrutide)

Phase 2 data showed ~24% mean weight loss at 48 weeks at the 12 mg dose — the largest mean effect of any weight-loss drug in modern trials. Phase 3 trials are ongoing. The glucagon component adds energy expenditure to the appetite-suppression mechanism, which is the leading hypothesis for the larger numbers. Final safety picture awaits Phase 3 reads.

GLP-1 + glucagon (Survodutide, Mazdutide)

Two-receptor versions of the triple-agonist concept. Survodutide's Phase 2 SYNCHRONIZE data showed ~19% weight loss at 46 weeks. Mazdutide showed similar results in Chinese trials. Both are now in Phase 3.

Amylin (Cagrilintide; CagriSema combination)

Cagrilintide alone produces ~10% weight loss. The CagriSema combination (Cagrilintide + Semaglutide) in Phase 3 trials produced ~15–22% depending on the specific trial cohort and dose. The amylin mechanism is genuinely complementary to GLP-1 — different receptor, partially different brain circuitry — and the combination is the leading "second-generation" GLP-1 strategy from Novo Nordisk.

Oral small-molecule GLP-1 (Orforglipron)

Not a peptide structurally, but works on the same receptor. Phase 3 ATTAIN data showed ~14% weight loss at 36 weeks at the highest dose. The advantage is oral dosing (no injection), which expands the addressable population significantly. Expected FDA decision in 2026.

Research-use peptides (AOD-9604, HGH Fragment 176-191)

These are fragments of growth hormone marketed as fat-loss peptides. Human evidence is weak: small studies in the 2000s showed minimal or no weight loss compared with placebo at the doses tested. They appear repeatedly in informal "weight loss stack" recommendations; the evidence does not support them as primary weight-loss agents.

What to expect on a GLP-1 / GIP / glucagon agonist

Onset. Appetite suppression typically begins within days of the first dose. Weight loss accumulates over months — most of the trial weight loss happens in the first 6–9 months, then plateaus.

Titration. Every approved drug in this class titrates up over 4–16 weeks. This is necessary — the dose-limiting side effect (nausea) requires the body to adapt. Starting at full dose is not viable.

Side effects. Nausea (20–40% of patients in trials), vomiting, diarrhea or constipation, occasional fatigue. Most are dose-related and improve over 4–8 weeks. A small fraction of patients tolerate the class poorly enough to discontinue. See the full safety summary in are peptides safe?.

Muscle loss alongside fat loss. Modern trials report 20–40% of total weight loss is lean mass. Resistance training and protein-prioritization during weight loss reduces but does not eliminate this. People who lose weight rapidly with no resistance training will lose a meaningful amount of lean mass.

Discontinuation rebound. Most weight is regained within 12–24 months of stopping, in the absence of behavioral change. The drugs are not "cures" — they are tools that work while taken, like blood-pressure medication.

How to compare options

A useful decision tree for someone working with a prescribing clinician:

Want the longest track record, simplest dosing? Semaglutide.
Want the largest weight-loss effect from a currently-approved drug? Tirzepatide.
Need an oral option (no injections)? Wait for Orforglipron FDA approval, or use an older oral GLP-1 (Rybelsus).
Have type 2 diabetes alongside obesity? All GLP-1 / GIP options are reasonable; Semaglutide and Tirzepatide both have T2D indications.
Have cardiovascular disease alongside obesity? Semaglutide has the strongest CV-outcome data (SELECT). Tirzepatide CV trial (SURPASS-CVOT) reads in 2026–2027.
Cannot tolerate GLP-1 side effects? Some patients tolerate Tirzepatide better than Semaglutide at matched-efficacy doses; amylin (Cagrilintide) has a different side-effect profile and may suit non-responders.

Cost reality

US list prices for the on-label brand-name versions are roughly $1,000–1,400 per month before insurance. With insurance coverage they can drop substantially; without, patients typically use either telehealth-channel pricing, compounded versions (legally murky and tightening), or specific manufacturer discount programs. Compounded GLP-1 supply has constricted sharply since FDA tightened the 503A list in 2024–2025.

This is the practical reason "research-use" peptide-class GLP-1s appear in grey-market sources — the approved drugs are expensive. The trade-off is the product-quality risk discussion in the safety article.

Practical next steps

Talk to a clinician. The decision tree above is for organizing the conversation, not replacing it.
Get baseline labs (CMP, lipids, A1C, TSH) and a thyroid-history screen before starting any GLP-1 / GIP agonist.
Use the reconstitution calculator to validate your dosing math if you receive a multi-dose vial.
Read how to inject peptides and where to inject peptides before your first dose.
Plan resistance training and a protein-prioritized diet alongside the drug to preserve lean mass.